Product Description: Pateclizumab (MLTA3698A) is a humanized antibody against lymphotoxin α (LTα), a transiently expressed cytokine on activated B and T cells (Th1, Th17), which are implicated in rheumatoid arthritis (RA) pathogenesis[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Brinda Emu, et al. Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial.
CAS Number: 1202526-59-7
Molecular Weight: N/A
Compound Purity: 96.75
Research Area: Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: Others